0.61
+0.0396(+7.00%)
Currency In USD
| Previous Close | 0.57 |
| Open | 0.56 |
| Day High | 0.72 |
| Day Low | 0.56 |
| 52-Week High | 6.28 |
| 52-Week Low | 0.49 |
| Volume | 14.78M |
| Average Volume | 4.22M |
| Market Cap | 74.74M |
| PE | -1.08 |
| EPS | -0.56 |
| Moving Average 50 Days | 1.51 |
| Moving Average 200 Days | 1.98 |
| Change | 0.04 |
If you invested $1000 in Mersana Therapeutics, Inc. (MRSN) since IPO date, it would be worth $43.21 as of February 05, 2025 at a share price of $0.605. Whereas If you bought $1000 worth of Mersana Therapeutics, Inc. (MRSN) shares 5 years ago, it would be worth $85.69 as of February 05, 2025 at a share price of $0.605.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 30, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
GlobeNewswire Inc.
Jan 10, 2025 11:02 AM GMT
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ETCAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
GlobeNewswire Inc.
Jan 10, 2025 11:00 AM GMT
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile- Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously treated with topoisomerase-1 inhi